Monopar Therapeutics Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $71.06
- 52-Week Range
- $50.07 – $124.82
- Market Cap
- $479.46M
- P/E (TTM)
- —
- EPS (TTM)
- -2.44
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.77
- PEG Ratio
- —
- Return on Equity
- -15.34%
- Return on Assets
- -11.61%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 43.55
- Debt/Equity
- 0.00
- Total Debt
- $357.26K
- Free Cash Flow
- $-9.40M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $350.37M
Market Snapshot
About
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing proprietary therapeutics for cancer patients. The company focuses on camsirubicin for advanced soft tissue sarcoma and MNPR-101 for advanced cancers.